- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05600257
The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study
November 1, 2022 updated by: Chen-Pin Chou, Kaohsiung Veterans General Hospital.
To investigate whether digital breast tomosynthesis (DBT) benefits survival improvement.
Study Overview
Detailed Description
To suggest DBT for specific populations, compare the overall survival rate of women with digital mammography (DM) to the DBT screening for women with particular characteristics.
Study Type
Observational
Enrollment (Actual)
1517
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kaohsiung, Taiwan, 813
- Kaohsiung Veterans General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Individuals were diagnosed with breast cancer according to the International Disease Classification Criteria from September 2011 to December 2015.
Description
Inclusion Criteria:
- individuals were diagnosed with breast cancer according to the International Disease Classification Criteria
Exclusion Criteria:
- no surgery or incomplete surgical pathology stage
- complete remission after neoadjuvant chemotherapy
- non-breast cancer death
- bilateral breast cancer
- male breast cancer
- no pre-surgery mammography image
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Screening cohort
Women received mammography screening
|
Image with digital breast tomosynthesis
Other Names:
Image with digital mammography
Other Names:
|
|
Diagnostic cohort
Women received clinical breast examination
|
Image with digital breast tomosynthesis
Other Names:
Image with digital mammography
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival rate
Time Frame: Up to 111 months
|
Compare the overall survival rate according to breast density type, cancer stage, mammography test type, and imaging modality.
|
Up to 111 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Chen-Pin Chou, MD, Kaohsiung Veterans General Hospital.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2011
Primary Completion (Actual)
August 31, 2021
Study Completion (Actual)
August 31, 2021
Study Registration Dates
First Submitted
October 26, 2022
First Submitted That Met QC Criteria
October 26, 2022
First Posted (Actual)
October 31, 2022
Study Record Updates
Last Update Posted (Actual)
November 4, 2022
Last Update Submitted That Met QC Criteria
November 1, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KSVGH22-CT11-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
The data that support the findings of this study are available on reasonable request from the corresponding author.
Some data are not publicly available due to their containing information that could compromise the privacy of research participants.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on DBT
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedSuicide | Borderline Personality DisorderUnited States
-
University Hospital, MontpellierINSERM 1061, " Neuropsychiatry: epidemiological and clinical research", MontpellierWithdrawnFemale | Borderline Personality DisorderFrance
-
Bogazici UniversityRecruitingEmotion RegulationTurkey (Türkiye)
-
Rivierduinen, Centre for Personality disorders...Erasmus Medical CenterUnknownBorderline Personality DisorderNetherlands
-
University of Maryland, BaltimoreRecruitingSuicide | PsychosisUnited States
-
University Hospital, Strasbourg, FranceNot yet recruitingEmotional Dysregulation | Addiction DisordersFrance
-
Centre for Addiction and Mental HealthNot yet recruitingClinical High Risk for Psychosis (CHR)Canada
-
Mental Health Services in the Capital Region, DenmarkUniversity of Copenhagen; Lundbeck FoundationCompletedSuicide | Borderline Personality DisorderDenmark
-
Rutgers, The State University of New JerseyCompletedBorderline Personality Disorder in AdolescenceUnited States
-
Rutgers, The State University of New JerseyNational Institute of Mental Health (NIMH)RecruitingHIV | Suicidal Ideation and Behavior | AIDS (Acquired Immune Deficiency Syndrome)United States